Puma Biotechnology Inc (PBYI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has a cash flow conversion efficiency ratio of 0.111x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.42 Million) by net assets ($130.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PBYI company net worth for the company's overall valuation and market capitalisation.
Puma Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Puma Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Puma Biotechnology Inc ranked by their cash flow conversion efficiency. Explore Puma Biotechnology Inc (PBYI) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Steel Union Co Ltd
TW:6581
|
0.035x |
|
Gevo Inc
NASDAQ:GEVO
|
-0.105x |
|
Waterstone Financial Inc
NASDAQ:WSBF
|
0.027x |
|
TAIDOC TECHNOLOGY CORP
TW:4736
|
0.024x |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653
|
0.034x |
|
Nanjing Inform Storage Equip
SHG:603066
|
-0.012x |
|
China Railway Prefabricated Construction Co Ltd
SHE:300374
|
-0.015x |
|
ElringKlinger AG
F:ZIL2
|
0.233x |
Annual Cash Flow Conversion Efficiency for Puma Biotechnology Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Puma Biotechnology Inc from 2007 to 2025. View Puma Biotechnology Inc (PBYI) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.34 Million | $41.80 Million | 0.321x | -24.08% |
| 2024-12-31 | $92.12 Million | $38.92 Million | 0.422x | -16.41% |
| 2023-12-31 | $53.44 Million | $27.01 Million | 0.505x | +169.00% |
| 2022-12-31 | $21.61 Million | $-15.83 Million | -0.732x | +91.32% |
| 2021-12-31 | $-2.45 Million | $20.65 Million | -8.442x | -6180.06% |
| 2020-12-31 | $-5.95 Million | $800.00K | -0.134x | -110.49% |
| 2019-12-31 | $17.46 Million | $22.38 Million | 1.281x | +282.40% |
| 2018-12-31 | $34.31 Million | $-24.10 Million | -0.703x | +78.29% |
| 2017-12-31 | $53.30 Million | $-172.50 Million | -3.236x | -379.22% |
| 2016-12-31 | $209.82 Million | $-141.70 Million | -0.675x | +9.95% |
| 2015-12-31 | $206.01 Million | $-154.50 Million | -0.750x | -13.71% |
| 2014-12-31 | $117.05 Million | $-77.20 Million | -0.660x | -0.63% |
| 2013-12-31 | $83.99 Million | $-55.05 Million | -0.655x | -92.03% |
| 2012-12-31 | $128.91 Million | $-44.00 Million | -0.341x | -916.91% |
| 2011-12-31 | $54.37 Million | $-1.83 Million | -0.034x | +99.97% |
| 2009-12-31 | $138.00 | $-16.82K | -121.848x | -2340.50% |
| 2008-12-31 | $-2.18K | $-11.83K | 5.438x | -- |
| 2007-12-31 | $0.00 | $-15.09 Million | x | -- |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more